Business Description
Aequus Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA0076361033
Description
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | -7.25 | |||||
| Debt-to-Equity | -1.05 | |||||
| Debt-to-EBITDA | -2.83 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -74.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -58.5 | |||||
| 3-Year EBITDA Growth Rate | -88.2 | |||||
| 3-Year EPS without NRI Growth Rate | -26 | |||||
| 3-Year FCF Growth Rate | -23.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.69 | |||||
| 9-Day RSI | 35.87 | |||||
| 14-Day RSI | 39.27 | |||||
| 6-1 Month Momentum % | -80 | |||||
| 12-1 Month Momentum % | -80 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | |||||
| Quick Ratio | 0.03 | |||||
| Days Inventory | 245.61 | |||||
| Days Sales Outstanding | 51.97 | |||||
| Days Payable | 725.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | -366.94 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.51 | |||||
| Operating Margin % | -601.94 | |||||
| Net Margin % | -647.94 | |||||
| FCF Margin % | -600.24 | |||||
| ROA % | -256.47 | |||||
| ROIC % | -44.58 | |||||
| ROC (Joel Greenblatt) % | -396.08 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.5 | |||||
| EV-to-EBIT | -2.93 | |||||
| EV-to-EBITDA | -3.1 | |||||
| EV-to-Revenue | 17.38 | |||||
| EV-to-FCF | -2.9 | |||||
| Earnings Yield (Greenblatt) % | -34.13 | |||||
| FCF Yield % | -373.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aequus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.413 | ||
| EPS (TTM) (C$) | -0.025 | ||
| Beta | -0.27 | ||
| Volatility % | 119.49 | ||
| 14-Day RSI | 39.27 | ||
| 14-Day ATR (C$) | 0.000741 | ||
| 20-Day SMA (C$) | 0.00575 | ||
| 12-1 Month Momentum % | -80 | ||
| 52-Week Range (C$) | 0.005 - 0.04 | ||
| Shares Outstanding (Mil) | 132.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aequus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aequus Pharmaceuticals Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aequus Pharmaceuticals Inc Frequently Asked Questions
What is Aequus Pharmaceuticals Inc(TSXV:AQS)'s stock price today?
The current price of TSXV:AQS is C$0.01. The 52 week high of TSXV:AQS is C$0.04 and 52 week low is C$0.01.
When is next earnings date of Aequus Pharmaceuticals Inc(TSXV:AQS)?
The next earnings date of Aequus Pharmaceuticals Inc(TSXV:AQS) is .
Does Aequus Pharmaceuticals Inc(TSXV:AQS) pay dividends? If so, how much?
Aequus Pharmaceuticals Inc(TSXV:AQS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers